Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-D-glucose in combination therapy

Journal of Breast Cancer

Volumn 15, Issue 2, 2012, Pages 141-147

  Aghaee, Fahimeh ^a   Islamian, Jalil Pirayesh ^a   Baradaran, Behzaad ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

2 deoxy D glucose; Breast neoplasms; Combined modality therapy; Radiation; Tumor cell line

Indexed keywords

CISPLATIN; DEOXYGLUCOSE; DOXORUBICIN; GLUCOSE TRANSPORTER 1; RADIOSENSITIZING AGENT;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL STRESS; CHEMOSENSITIVITY; CYTOTOXICITY; DNA REPAIR; DRUG EFFICACY; GLIOMA; GLYCOLYSIS; HUMAN; IONIZING RADIATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; TUMOR SPHEROID;

EID: 84865140782     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2012.15.2.141     Document Type: Review

References (33)

1. Genetics of breast cancer for the practicing surgeon. Agashe PP, Shrikhande SV. http://www.bhj.org/journal/2001_4304_oct/review_537.htm. Accessed June 12th, 2011.
2. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, et al. Novel therapeutic approach: ligands for PPARgamma and retinoid re-ceptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002;74:155-65.
3. Kaabinejadian S, Fouladdel SH, Ramezani M, Azizi E. p53 expression in MCF7, T47D and MDA-MB 468 breast cancer cell lines treated with adriamycin using RT-PCR and immunocytochemistry. J Biol Sci 2008; 8:380-5.
4. de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039-43.
5. Han W, Kang SY; Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 2010;119:193-200.
6. Rodeh HJ, Eisel D, Frost I. Apoptosis, Cell Death and Cell Proliferation. 3rd ed. Mannheim: Roche Diagnostics GmbH; 2000. p.2-6.
7. Types of breast cancer: ER positive, HER2 positive, and triple negative. WebMD. http://www.webmd.com/breast-cancer/breast-cancer-typeser-positive-her2-positive. Accessed August 2nd, 2010.
8. Breast cancer: tumor biology. Winship Cancer Institute. http://www. cancerquest.org/breast-cancer-molecular-biology. Accessed August 4th, 2010.
9. Cobb JP, Hotchkiss RS, Karl IE, Buchman TG. Mechanisms of cell injury and death. Br J Anaesth 1996;77:3-10.
10. Ghilotti M, Pierotti MA, Gariboldi M. Molecular markers for prediction of risk of radiation-related injury to normal tissue. J Nucleic Acids Investig 2010;1:55-61.
11. Dwarkanath BS, Zolzer F, Chandana S, Bauch T, Adhikari JS, Muller WU, et al. Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines. Int J Radiat Oncol Biol Phys 2001;50:1051-61.
12. Schwarz SB, Schaffer PM, Kulka U, Ertl-Wagner B, Hell R, Schaffer M. The effect of radio-adaptive doses on HT29 and GM637 cells. Radiat Oncol 2008;3:12.
13. Kunigal S, Lakka SS, Joseph P, Estes N, Rao JS. Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors. Clin Cancer Res 2008; 14:3617-26.
14. Gupta S, Farooque A, Adhikari JS, Singh S, Dwarakanath BS. Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors. J Cancer Res Ther 2009;5 Suppl 1:S16-20.
15. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BA, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 1996;35:103-11.
16. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-46.
17. Aft RL, Zhang FW, Gius D. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer 2002;87: 805-12.
18. Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 2004;53:116-22.
19. Sinthupibulyakit C, Grimes KR, Domann FE, Xu Y, Fang F, Ittarat W, et al. p53 is an important factor for the radiosensitization effect of 2-deoxy-D-glucose. Int J Oncol 2009;35:609-15.
20. Ahmad IM, Mustafa EH, Mustafa NH, Tahtamouni LH, Abdalla MY. 2DG enhances the susceptibility of breast cancer cells to doxorubicin. Cent Eur J Biol 2010;5:739-48.
21. Zhang F, Aft RL. Chemosensitizing and cytotoxic effects of 2-deoxy-Dglucose on breast cancer cells. J Cancer Res Ther 2009;5 Suppl 1:S41-3.
22. Kalia VK, Prabhakara S, Narayanan V. Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy. J Cancer Res Ther 2009;5 Suppl 1:S57-60.
23. Dwarakanath BS. Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro. J Cancer Res Ther 2009;5 Suppl 1:S27-31.
24. Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann N Y Acad Sci 2000;899:349-62.
25. Aykin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz DR. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 2009; 418:29-37.
26. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
27. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 2007; 67:3364-70.
28. Jain VK, Kalia VK, Sharma R, Maharajan V, Menon M. Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. Int J Radiat Oncol Biol Phys 1985;11:943-50.
29. Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D, Anderson BO. Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. J Surg Res 1998;76:22-6.
30. Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000;275:39174-81.
31. Ahmad IM, Abdalla MY, Aykin-Burns N, Simons AL, Oberley LW, Domann FE, et al. 2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress. Free Radic Biol Med 2008;44:826-34.
32. Singh G, Lakkis CL, Laucirica R, Epner DE. Regulation of prostate cancer cell division by glucose. J Cell Physiol 1999;180:431-8.
33. Zhao Y, Liu H, Liu Z, Ding Y, LeDoux SP, Wilson GL, et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 2011;71:4585-97.